Popular Trials
Nicotinic Acetylcholine Receptor Partial Agonist
Varenicline + NRT for Smoking Cessation
Recruiting2 awardsPhase 4
Houston, Texas
This trial is comparing varenicline to nicotine replacement therapy to see if varenicline is more effective in helping patients quit smoking. Varenicline is a drug that acts the same way as nicotine in the brain but is not habit-forming.
Nicotinic Receptor Partial Agonist
CHANTIX (Varenicline) for Smoking Cessation after Acute Coronary Syndrome
Recruiting4 awardsPhase 4
Newark, New Jersey
This trial looks at the role of a nicotine antagonist in helping patients who have had a heart attack or other acute coronary syndrome to stop smoking.
Nicotinic Acetylcholine Receptor Partial Agonist
Varenicline +1 More for Smoking
Recruiting4 awardsPhase 4
Toronto, Ontario
This study is a randomized, double-blind, placebo-controlled clinical trial which evaluates the efficacy of preoperative smoking counseling and varenicline (a medication approved by Health Canada and FDA for quitting smoking) to provide long term smoking cessation (i.e., abstinence for at least one year) in surgical patients. The primary hypothesis is as follows: "A significant percentage of surgical patients will be receptive to smoking cessation interventions in the pre-admission clinic and will refrain from smoking at 24 and 52 weeks after starting the treatment." The secondary hypothesis is as follows: "Patients who receive interventions but do not quit smoking will have reduced number of cigarettes consumed/day or improved their readiness to quit smoking at 24 and 52 weeks after starting the treatment."
Smoking Cessation Agent
Varenicline for Smoking
Recruiting2 awardsPhase 2
Vancouver, British Columbia
The main hypotheses guiding the study are: 1. Stable methadone maintenance patients receiving varenicline will be more likely to maintain abstinence than patients receiving placebo 2. There will be no differences in the type and number of symptoms reported between stable methadone maintenance patients receiving varenicline and placebo 3. There will be no changes in methadone dosage between abstinent and non-abstinent smokers 4. There will be no differences in efficacy, withdrawal symptoms, and safety of varenicline between male and female participants
Popular Filters
Phase 3 Trials
Behavioral Intervention
Tailored behavioral intervention +6 More for Nicotine Addiction
Recruiting4 awardsPhase 3
Iowa City, Iowa
The project is designed to examine the effectiveness of strategies to increase access to treatment for tobacco use and dependence among rural Veteran smokers. In addition, it will examine whether tailored treatment that is designed to address common comorbid conditions that are related to cigarette smoking enhances success with quitting relative to enhanced standard of care. The investigators hypothesize that participants assigned to the tailored tobacco cessation intervention will report greater cessation rates at six months. The investigators also anticipate more favorable outcomes on measures of depressive symptoms, alcohol use, and body weight.
Nicotinic Acetylcholine Receptor Partial Agonist
Varenicline + PSF-M for Smoking Cessation in HIV/AIDS
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial tests a mobile app and a medication to help people with HIV quit smoking. The app provides tips and support, while the medication reduces cravings. The study aims to see if this combination is more effective than standard care.
Trials With No Placebo
Smoking Cessation Agent
Varenicline for Tardive Dyskinesia
Recruiting5 awardsPhase 4
Philadelphia, Pennsylvania
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder patients who are actively smoking and have pre-existing TD while receiving stable doses of antipsychotics. Subjects will be followed after a 2 week baseline period to assess changes in smoking status and neurological symptoms using standardized rating scales. The aim is to examine clinically significant effects on antipsychotic-induced neurological side effects that may warrant further investigation.
Smoking Cessation Aid
Varenicline +11 More for Smokeless Tobacco
Recruiting3 awards7 criteria
Iowa City, Iowa
This is a pilot study designed in an effort to develop and improve access to effective treatments for tobacco use in rural Veterans using a tailored intervention approach. Specifically, we will evaluate a combined behavioral and pharmacological smokeless tobacco cessation which concomitantly addresses comorbid issues commonly experienced by rural tobacco users including elevated depressive symptoms, risky alcohol use, and concerns about weight gain. The objectives are to: 1. Evaluate the feasibility of an individually-tailored telephone intervention for rural smokeless tobacco users 2. Examine the impact of the intervention on treatment utilization, patient satisfaction, and smokeless tobacco cessation.
Behavioral Intervention
Tailored behavioral intervention +6 More for Nicotine Addiction
Recruiting4 awardsPhase 3
Iowa City, Iowa
The project is designed to examine the effectiveness of strategies to increase access to treatment for tobacco use and dependence among rural Veteran smokers. In addition, it will examine whether tailored treatment that is designed to address common comorbid conditions that are related to cigarette smoking enhances success with quitting relative to enhanced standard of care. The investigators hypothesize that participants assigned to the tailored tobacco cessation intervention will report greater cessation rates at six months. The investigators also anticipate more favorable outcomes on measures of depressive symptoms, alcohol use, and body weight.
Behavioural Intervention
Smoking Cessation Treatment for Head & Neck Cancer Patients
Recruiting1 awardPhase < 1
Houston, Texas
This trial is designed to study and compare the effectiveness of two types of counseling for cancer patients who want to quit smoking: Acceptance and Commitment Therapy (ACT) and Motivational and Behavioral Counseling (MBC).
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.